Aura Biosciences (NASDAQ:AURA) Shares Up 9.2% - What's Next?

Key Points

• Shares jumped 9.2% to about $9.12 on Tuesday with trading volume up ~84%, reflecting heightened investor interest and intraday volatility.
• A new CEO, Natalie Holles, was named and the company says patient screening has accelerated with near‑completion of enrollment in the Phase 3 CoMpass trial for bel‑sar (AU‑011), a potential registration‑enabling milestone if results are positive.
• Aura priced an underwritten public financing expected to raise roughly $260.3M (39.6M common shares at $6.00 plus pre‑funded warrants), which funds late‑stage work but brings meaningful dilution risk and possible near‑term selling pressure.

Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) shares rose 9.2% on Tuesday . The company traded as high as $9.23 and last traded at $9.12. Approximately 490,433 shares changed hands during mid-day trading, an increase of 84% from the average daily volume of 267,008 shares. The stock had previously closed at $8.35.

More Aura Biosciences News

Here are the key news stories impacting Aura Biosciences this week:

• Positive Sentiment: Natalie Holles named CEO and President, bringing commercial and rare‑disease operational experience; management change is being framed as a move to accelerate late‑stage development and commercialization efforts. Read More.
• Positive Sentiment: Company reports accelerated patient screening and near‑completion of enrollment in the Phase 3 CoMpass trial for bel‑sar (AU‑011), a value‑creating clinical milestone if positive and supportive of a registration path. Read More.
• Positive Sentiment: Aura priced an underwritten offering expected to raise roughly $260.3M, with management saying ~$205.1M will fund clinical programs and registration‑enabling activities — reduces near‑term cash risk and finances late‑stage work. Read More.
• Neutral Sentiment: Multiple outlets noted pre‑market moves and broader market pressure that briefly affected AURA quotes; this is market noise rather than company‑specific news. Read More.
• Neutral Sentiment: Formal GlobeNewswire filing details the offering terms: 39,591,000 common shares at $6.00 and up to 3.8M pre‑funded warrants, plus a 30‑day underwriter option; close expected May 5, 2026 (subject to conditions). Useful for confirming mechanics. Read More.
• Negative Sentiment: Size of the offering (39.6M shares plus warrants, with a further underwriter option) creates meaningful dilution risk and potential near‑term selling pressure; investors will weigh dilution against the funding benefit. Read More.
• Negative Sentiment: HC Wainwright projects weaker earnings for Aura, adding analyst pressure and signaling continued investor scrutiny on near‑term fundamentals and the risk profile of trial outcomes. Read More.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on AURA shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Aura Biosciences in a research note on Friday, March 27th. Wall Street Zen upgraded Aura Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday, April 4th. Finally, HC Wainwright upped their price objective on Aura Biosciences from $22.00 to $24.00 and gave the stock a "buy" rating in a research note on Wednesday, April 29th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $21.50.

Aura Biosciences Price Performance

The stock has a market cap of $577.80 million, a P/E ratio of -5.01 and a beta of 0.37. The stock's 50-day moving average is $6.49 and its two-hundred day moving average is $5.99.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.06. On average, analysts anticipate that Aura Biosciences, Inc. will post -1.63 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Conor Kilroy sold 11,738 shares of Aura Biosciences stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $7.02, for a total value of $82,400.76. Following the completion of the transaction, the insider owned 217,835 shares in the company, valued at approximately $1,529,201.70. This trade represents a 5.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Los Pinos Elisabet De sold 47,648 shares of Aura Biosciences stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $5.06, for a total value of $241,098.88. Following the completion of the transaction, the insider owned 409,815 shares of the company's stock, valued at approximately $2,073,663.90. This trade represents a 10.42% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 116,305 shares of company stock worth $611,230. Insiders own 6.30% of the company's stock.

Institutional Trading of Aura Biosciences

Institutional investors have recently bought and sold shares of the stock. XTX Topco Ltd increased its position in Aura Biosciences by 145.2% during the fourth quarter. XTX Topco Ltd now owns 60,811 shares of the company's stock valued at $331,000 after acquiring an additional 36,006 shares during the last quarter. Wellington Management Group LLP raised its position in Aura Biosciences by 10.7% in the 4th quarter. Wellington Management Group LLP now owns 140,959 shares of the company's stock worth $768,000 after purchasing an additional 13,647 shares during the period. Millennium Management LLC lifted its stake in Aura Biosciences by 233.3% in the fourth quarter. Millennium Management LLC now owns 617,338 shares of the company's stock worth $3,364,000 after purchasing an additional 432,117 shares during the last quarter. Trexquant Investment LP purchased a new position in shares of Aura Biosciences during the fourth quarter valued at approximately $234,000. Finally, ExodusPoint Capital Management LP grew its stake in shares of Aura Biosciences by 18.4% during the fourth quarter. ExodusPoint Capital Management LP now owns 51,419 shares of the company's stock valued at $280,000 after buying an additional 7,998 shares during the last quarter. 96.75% of the stock is currently owned by institutional investors.

About Aura Biosciences

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company's platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.